XTL Biopharmaceuticals Ltd.

XTLBNASDAQHealthcare● Active

$2.23

+$0.17(+8.25%)

Market Cap$5275304

P/E Ratio—

52W High$10.28

52W Low$2.065

Avg Volume1.9M

Open$2.27

Beta0.56

Overview

XTL Biopharmaceuticals Ltd. (XTLB) Earnings: Dates, EPS & Revenue History

Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.

XTLB · earnings · updated Jun 8, 2026

Latest Earnings

Q4 FY2025Report Date: Dec 29, 2025

EPS Actual

-$0.36

Revenue

—

Fiscal Period

Q4 FY2025

FY ends December

Report Date

Dec 29, 2025

After Market Close

XTLB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.

Next Earnings Date

Days Away

days

Expected Date

Sep 1, 2026

Fiscal Period

Q3 FY2026

Release Time

◌ Time TBD (Unconfirmed)

EPS Est.

—

Days Away85

Expected DateSep 1, 2026

Fiscal PeriodQ3 FY2026

Release TimeTime TBD (Unconfirmed)

EPS Est.—

EPS & Revenue vs. Estimates

Actual (Beat)

Actual (Miss)

Estimated

Earnings History

Period	Report Date	EPS Est.	EPS Actual	EPS Surpr.	Revenue	Rev. Est.	Rev. Surpr.
◌ Q2 FY2026	Apr 29, 2026	—	—	—	—	—	—
— Q4 FY2025	Dec 29, 2025	—	-$0.36	—	—	—	—
— Q2 FY2025	Jun 30, 2025	—	$0.10	—	—	—	—
— Q2 FY2025	Jun 30, 2025	—	$0.10	—	—	—	—
— Q1 FY2025	Jan 1, 2025	—	-$0.04	—	$0.00B	—	—
— Q4 FY2024	Dec 30, 2024	—	-$0.13	—	$0.00B	—	—
— Q3 FY2024	Sep 26, 2024	—	-$0.07	—	—	—	—
— Q2 FY2024	May 13, 2024	—	$0.10	—	—	—	—

Q2 FY2026

Apr 29, 2026

EPS Actual

—

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q4 FY2025

Dec 29, 2025

EPS Actual

-$0.36

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2025

Jun 30, 2025

EPS Actual

$0.10

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2025

Jun 30, 2025

EPS Actual

$0.10

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q1 FY2025

Jan 1, 2025

EPS Actual

-$0.04

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q4 FY2024

Dec 30, 2024

EPS Actual

-$0.13

EPS Est.

—

EPS Surpr.

—

Revenue

$0.00B

Q3 FY2024

Sep 26, 2024

EPS Actual

-$0.07

EPS Est.

—

EPS Surpr.

—

Revenue

—

Q2 FY2024

May 13, 2024

EPS Actual

$0.10

EPS Est.

—

EPS Surpr.

—

Revenue

—

No analyst estimates available for XTLB.

Earnings Price Reaction

Closing price one trading day before vs. one trading day after each earnings release.

Period	Report Date	EPS Beat/Miss	Price Before	Price After	1D Reaction
— Q4 FY2025	Dec 29, 2025	—	$2.96	$2.69	-9.12%
— Q2 FY2025	Jun 30, 2025	—	$4.64	$4.56	-1.72%
— Q2 FY2025	Jun 30, 2025	—	$4.64	$4.56	-1.72%
— Q1 FY2025	Jan 1, 2025	—	$8.12	$7.88	-2.96%
— Q4 FY2024	Dec 30, 2024	—	$8.28	$7.44	-10.14%
— Q3 FY2024	Sep 26, 2024	—	$10.36	$10.12	-2.32%
— Q2 FY2024	May 13, 2024	—	$10.24	$11.68	+14.06%
— Q1 FY2024	Mar 27, 2024	—	$12.28	$10.80	-12.05%

Q4 FY2025-9.12%

Report Date

Dec 29, 2025

EPS Beat/Miss

—

Price Before

$2.96

Price After

$2.69

Q2 FY2025-1.72%

Report Date

Jun 30, 2025

EPS Beat/Miss

—

Price Before

$4.64

Price After

$4.56

Q2 FY2025-1.72%

Report Date

Jun 30, 2025

EPS Beat/Miss

—

Price Before

$4.64

Price After

$4.56

Q1 FY2025-2.96%

Report Date

Jan 1, 2025

EPS Beat/Miss

—

Price Before

$8.12

Price After

$7.88

Q4 FY2024-10.14%

Report Date

Dec 30, 2024

EPS Beat/Miss

—

Price Before

$8.28

Price After

$7.44

Q3 FY2024-2.32%

Report Date

Sep 26, 2024

EPS Beat/Miss

—

Price Before

$10.36

Price After

$10.12

Q2 FY2024+14.06%

Report Date

May 13, 2024

EPS Beat/Miss

—

Price Before

$10.24

Price After

$11.68

Q1 FY2024-12.05%

Report Date

Mar 27, 2024

EPS Beat/Miss

—

Price Before

$12.28

Price After

$10.80

Beat Rate0 / 8 quarters

Largest Move+14.06% (Q2 FY2024)

Data: FMP /historical-price-eod/full · field: close

About Earnings & Data Methodology

XTL Biopharmaceuticals Ltd. (XTLB) most recently reported earnings on December 29, 2025 for Q4 FY2025, posting EPS of $-0.36 (in line with the analyst consensus of —). The next XTLB earnings date is expected around September 1, 2026.

Each quarter, investors track XTLB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. XTLB revenue tab →

Earnings Glossary

EPS (Earnings Per Share)

Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.

Earnings Surprise %

(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.

Beat / Miss / In-Line

Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.

BMO / AMC

Before Market Open / After Market Close. Two windows when companies typically release results.

Fiscal Quarter

XTLB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.

Analyst Consensus

Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.

Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.

Revenue Price history Financial statements Forecast Dividends Market cap

Frequently asked questions

XTLB earnings · 4 questions

XTL Biopharmaceuticals Ltd.'s next earnings report is expected around September 1, 2026. XTLB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; XTLB historically reports after market close (AMC).

XTLB earnings datewhen is XTLB earningsXTLB next earnings datewhen does XTLB report earningsXTLB earnings calendar

▸ Source: FMP · XTL Biopharmaceuticals Ltd. SEC filings · US GAAP · XTL Biopharmaceuticals Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026